Protara Therapeutics is a clinical-stage biopharmaceutical company focused on identifying and developing transformative therapies for the treatment of cancer and rare diseases. Co.'s primary oncology program is TARA-002 in non-muscle invasive bladder cancer. Co. is also pursuing TARA-002 in lymphatic malformations, which are rare, non-malignant cysts of the lymphatic vascular system. The third development program in Co.'s portfolio is intravenous Choline Chloride, an investigational phospholipid substrate replacement therapy initially in development for patients receiving parenteral nutrition, who have intestinal failure associated liver disease. The TARA average annual return since 2014 is shown above.
The Average Annual Return on the TARA average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TARA average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TARA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free TARA Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
